VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for its lead BiTAC ® T-cell engager ...

Advanced biliary tract cancer (BTC) includes cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma. BTC is a rare and aggressive group of cancers, carrying one of the worst prognoses in ...

Researchers recently enhanced the titer of a cell line still in development to produce adenovirus viral vectors by 7.5-fold, and without the risk of also producing replication-competent adenoviruses ...